Anil K Sood MD

Obstetrics & Gynecology•Houston, TX

Gynecologic Oncology

Physician

Join to View Full Profile

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Gynecologic Oncology, 1995 - 1996
University of FloridaResidency, Obstetrics and Gynecology, 1991 - 1995
University of North Carolina at Chapel Hill School of MedicineClass of 1991

Certifications & Licensure

FL State Medical License 1993 - 2027
GA State Medical License 2023 - 2026
TX State Medical License 2002 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
AZ State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TN State Medical License 2023 - 2025
IA State Medical License 1995 - 2003
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology
Join now to see all

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2010-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2009-2013
Elected Member The American Society for Clinical Investigation, 2009
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2007 Jan 01
Completed
Phase 1, Phase 2
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin Start of enrollment: 2008 Feb 01
Active, not recruiting
Phase 1
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Start of enrollment: 2010 Apr 14
Completed
Phase 2

Publications & Presentations

PubMed

Gain-of-Function Chromatin Remodeling Activity of Oncogenic FOXL2C134W Reprograms Glucocorticoid Receptor Occupancy to Drive Granulosa Cell Tumors.
Thomas Welte, Veena K Vuttaradhi, Eleonora Y Khlebus, Allison Brodsky, Alejandra Flores Legarreta
Cancer Research. 2025-03-03
IMGN853 Induces Autophagic Cell Death in Combination Therapy for Ovarian Cancer.
Anca Chelariu-Raicu, Thanh Chung Vu, Sujanitha Umamaheswaran, Elaine Stur, Pahul Hanjra
Cancer Research Communications. 2025-03-01
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
Amma Asare, Rebecca Ann Previs, Daniel Spinosa, Bryan Fellman, Amelia L Scott
Gynecologic Oncology. 2025-02-22

Journal Articles

Minimally Invasive Surgery and Risk of Capsule Rupture for Women with Early-Stage Ovarian Cancer
Koji Matsuo, Lynda D Roman, Anil K Sood, JAMA Oncology
Minimally Invasive Surgery and Risk of Capsule Rupture for Women with Early-Stage Ovarian Cancer
Lynda D Roman, Anil K Sood, JAMA Oncology
EGFL6 Promotes Breast Cancer by Simultaneously Enhancing Cancer Cell Metastasis and Stimulating Tumor Angiogenesis
Xuejun Fan, Anil K Sood, Nature
CD44-Targeted PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer
Anil Sood, MD, Clinical Cancer Research
FABP4 as a Key Determinant of Metastatic Potential of Ovarian Cancer
Jinsong Liu, Anil K Sood, Nature
Paclitaxel Sensitivity of Ovarian Cancer Can Be Enhanced by Knocking down Pairs of Kinases That Regulate MAP4 Phosphorylation and Microtubule Stability
Robert C Bast, Anil K Sood, Clinical Cancer Research
Life Stress as a Risk Factor for Sustained Anxiety and Cortisol Dysregulation During the First Year of Survivorship in Ovarian Cancer
Anil K Sood, Premal H Thaker, Laila Dahmoush, Cancer
A-to-I miR-378a-3p Editing Can Prevent Melanoma Progression via Regulation of PARVA Expression
Anil Sood, MD, Nature
Stress Hormones Promote EGFR Inhibitor Resistance in NSCLC: Implications for Combinations with Β-blockers
Hai Tran, Anil K Sood, John V Heymach, Roy Herbst, Lecia V Sequist, Edward S Kim, Science Magazine
Join now to see all

Authored Content

Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple Negative Breast Cancer via SMAD2/3/4 and mTORC2 SignalingJuly 2018

Press Mentions

Funda Meric-Bernstam, M.D., Elected to National Academy of MedicineOctober 21st, 2024
Most Cancers of the Unknown Main Survivor: Why I Joined a Scientific Trial at MD AndersonSeptember 23rd, 2022
Cancer of the Unknown Primary Survivor: Why I Joined a Clinical Trial at MD AndersonSeptember 23rd, 2022
Join now to see all

Grant Support

Novel Biomarkers Predicting Blood Clots in Ovarian CancerUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Targeting uterine serous carcinoma with antibody-drug conjugatesUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
The University of Texas MD Anderson Cancer Center SPORE in Ovarian CancerUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
The University of Texas MD Anderson Cancer Center SPORE in Ovarian CancerUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Novel Biomarkers Predicting Blood Clots in Ovarian CancerUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
The University of Texas MD Anderson Cancer Center SPORE in Ovarian CancerUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
The SIK2 Inhibitor GRN-300 enhances PARP Inhibitor sensitivity and overcomes resistance by blocking homologous recombination (HR) DNA repair in ovarian cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Targeting uterine serous carcinoma with antibody-drug conjugatesUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
The SIK2 Inhibitor GRN-300 enhances PARP Inhibitor sensitivity and overcomes resistance by blocking homologous recombination (HR) DNA repair in ovarian cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Training of Academic Gynecologic OncologistsUNIVERSITY OF TX MD ANDERSON CAN CTR2005–2026
Harnessing the power of exosomes for non-coding RNA deliveryUNIVERSITY OF TX MD ANDERSON CAN CTR2017–2025
Ovarian Cancer: Mechanisms Of Neuroendocrine RegulationNational Cancer Institute2005–2012
New Reagents For Synthesis Of High Potency SirnaNational Institute Of General Medical Sciences2010–2011
Ovarian Cancer PlateletsNational Center For Research Resources2010–2011
Texas Center For Cancer NanomedicineNational Cancer Institute2010–2011
P2 - Targeting Dii4-Notch Signaling In Ovarian CancerNational Cancer Institute2010–2011
Nanotechnology Platforms For Targeting Ovarian Cancer VasculatureNational Cancer Institute2010–2011
EPHA2 Targeting In Uterine CarcinomaNational Cancer Institute2010–2011
Subcellular Localization Of NanoparticlesNational Institute Of General Medical Sciences2010
Subcellular Localization Of NanoparticlesNational Institute Of General Medical Sciences2009–2010
Cell-Specific Targeting Of Ovarian Cancer VasculatureNational Cancer Institute2008–2009
Tumor Metastasis: Biobehavioral MechanismsNational Cancer Institute2004–2009
Anorectal Manometry To Asscess Rectal Dysfunction Following HysterectomyNational Center For Research Resources1998–2000